Cariad Chester
Directeur/Membre du Conseil chez Plexium, Inc.
Profil
Cariad Chester is currently the Director at Plexium, Inc. since 2022 and a Partner at both The Column Group LLC and TCG Crossover Management LLC since 2021.
Previously, Cariad worked as the Managing Director at Aquilo Capital Management LLC from 2015 to 2021.
Additionally, Cariad held the position of Director at Tourmaline Sub, Inc. in 2023 and was a Director at Tourmaline Bio, Inc. Cariad completed their undergraduate degree at Swarthmore College.
Postes actifs de Cariad Chester
| Sociétés | Poste | Début |
|---|---|---|
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | 01/01/2021 |
Plexium, Inc.
 Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 23/02/2022 |
TCG Crossover Management LLC
 TCG Crossover Management LLC Investment ManagersFinance TCG Crossover Management LLC (TCG Crossover Management) is a venture capital firm founded in 2021 by Chen-Ming Yu. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/01/2021 |
Anciens postes connus de Cariad Chester
| Sociétés | Poste | Fin |
|---|---|---|
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Directeur/Membre du Conseil | 29/11/2023 |
Aquilo Capital Management LLC
 Aquilo Capital Management LLC Investment ManagersFinance Aquilo Capital Management LLC (Aquilo) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. Aquilo was founded in 2010 to manage investment funds and separately managed accounts for individual clients. | Analyst-Equity | 31/12/2021 |
Formation de Cariad Chester
| Swarthmore College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo Capital Management LLC (Aquilo) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. Aquilo was founded in 2010 to manage investment funds and separately managed accounts for individual clients. | Finance |
Plexium, Inc.
Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Health Technology |
TCG Crossover Management LLC
TCG Crossover Management LLC Investment ManagersFinance TCG Crossover Management LLC (TCG Crossover Management) is a venture capital firm founded in 2021 by Chen-Ming Yu. The firm is headquartered in Palo Alto, California. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |